JP6152092B2 - 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム - Google Patents

経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム Download PDF

Info

Publication number
JP6152092B2
JP6152092B2 JP2014510901A JP2014510901A JP6152092B2 JP 6152092 B2 JP6152092 B2 JP 6152092B2 JP 2014510901 A JP2014510901 A JP 2014510901A JP 2014510901 A JP2014510901 A JP 2014510901A JP 6152092 B2 JP6152092 B2 JP 6152092B2
Authority
JP
Japan
Prior art keywords
testosterone
gel
intranasal
testosterone gel
intranasal testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014510901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515038A5 (enExample
JP2014515038A (ja
Inventor
クレップナー，ウェイン
フォガーティ，シヴォーン
オベレガー，ワーナー
マエ，ポール，ジョゼ，ピエール，マリー
Original Assignee
エーセラス ファーマシューティカルズ コーポレーション
エーセラス ファーマシューティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーセラス ファーマシューティカルズ コーポレーション, エーセラス ファーマシューティカルズ コーポレーション filed Critical エーセラス ファーマシューティカルズ コーポレーション
Publication of JP2014515038A publication Critical patent/JP2014515038A/ja
Publication of JP2014515038A5 publication Critical patent/JP2014515038A5/ja
Application granted granted Critical
Publication of JP6152092B2 publication Critical patent/JP6152092B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014510901A 2011-05-15 2012-05-15 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム Expired - Fee Related JP6152092B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US61/486,324 2011-05-15
US201161486634P 2011-05-16 2011-05-16
US61/486,634 2011-05-16
PCT/IB2012/001127 WO2012156822A1 (en) 2011-05-15 2012-05-15 Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017056679A Division JP6594924B2 (ja) 2011-05-15 2017-03-22 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム

Publications (3)

Publication Number Publication Date
JP2014515038A JP2014515038A (ja) 2014-06-26
JP2014515038A5 JP2014515038A5 (enExample) 2015-07-09
JP6152092B2 true JP6152092B2 (ja) 2017-06-28

Family

ID=46579248

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2014510901A Expired - Fee Related JP6152092B2 (ja) 2011-05-15 2012-05-15 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2014510900A Pending JP2014513716A (ja) 2011-05-15 2012-05-15 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2017056679A Expired - Fee Related JP6594924B2 (ja) 2011-05-15 2017-03-22 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2018158566A Pending JP2018199701A (ja) 2011-05-15 2018-08-27 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2019173990A Active JP7017254B2 (ja) 2011-05-15 2019-09-25 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2020012807A Pending JP2020079257A (ja) 2011-05-15 2020-01-29 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2020157216A Pending JP2021001206A (ja) 2011-05-15 2020-09-18 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022034334A Pending JP2022078222A (ja) 2011-05-15 2022-03-07 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022076671A Pending JP2022105175A (ja) 2011-05-15 2022-05-06 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2014510900A Pending JP2014513716A (ja) 2011-05-15 2012-05-15 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2017056679A Expired - Fee Related JP6594924B2 (ja) 2011-05-15 2017-03-22 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2018158566A Pending JP2018199701A (ja) 2011-05-15 2018-08-27 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2019173990A Active JP7017254B2 (ja) 2011-05-15 2019-09-25 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2020012807A Pending JP2020079257A (ja) 2011-05-15 2020-01-29 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2020157216A Pending JP2021001206A (ja) 2011-05-15 2020-09-18 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022034334A Pending JP2022078222A (ja) 2011-05-15 2022-03-07 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022076671A Pending JP2022105175A (ja) 2011-05-15 2022-05-06 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用

Country Status (16)

Country Link
EP (3) EP2709588B1 (enExample)
JP (9) JP6152092B2 (enExample)
KR (10) KR20190117803A (enExample)
CN (4) CN110613679A (enExample)
AR (2) AR089553A1 (enExample)
AU (11) AU2012257490A1 (enExample)
BR (2) BR112013029336B1 (enExample)
CA (3) CA3034552C (enExample)
DK (1) DK2714006T3 (enExample)
EA (1) EA201391701A1 (enExample)
ES (1) ES2859784T3 (enExample)
IL (2) IL229400A0 (enExample)
MX (4) MX395212B (enExample)
PL (1) PL2714006T4 (enExample)
WO (2) WO2012156822A1 (enExample)
ZA (2) ZA201309264B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
MX395212B (es) * 2011-05-15 2025-03-21 Acerus Biopharma Inc Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal.
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2015054213A1 (en) * 2013-10-07 2015-04-16 Wotton Paul K Hematocrit modulation through needle assisted jet injection of testosterone
EP3107547A4 (en) 2014-02-19 2017-11-15 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
WO2016123317A1 (en) * 2015-01-28 2016-08-04 Prometheon Pharma, Llc Topical formulations of growth factors
CA2986444C (en) * 2015-06-29 2023-10-24 480 Biomedical, Inc. Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
ES2949053T3 (es) * 2016-01-07 2023-09-25 Viramal Ltd Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR102487355B1 (ko) 2016-04-25 2023-01-11 코스카 패밀리 리미티드 의료 전달 시스템
EP3478270A4 (en) * 2016-06-02 2019-11-27 Acerus Labs, Inc. HALF-RESISTANT AND VISCOUS LIQUID, NADAL FORMULATIONS OF CANNABINOIDS
KR102387241B1 (ko) * 2016-06-03 2022-04-15 엠 이티 피 파마 아게 다공성 부형제를 갖는 비강용 약제학적 조성물
HUE063346T2 (hu) 2017-01-20 2024-01-28 M et P Pharma AG Nazális gyógyszerészeti készítmények légszennyezõ anyagoknak való kitettség kockázatainak csökkentésére
US10764951B2 (en) * 2017-06-17 2020-09-01 Lg Electronics Inc. Registration method of user terminal in wireless communication system and apparatus therefor
KR102639913B1 (ko) 2017-11-17 2024-02-23 코스카 패밀리 리미티드 유체 전달 매니폴드를 위한 시스템 및 방법
AU2018371435B2 (en) * 2017-11-27 2023-12-14 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration
CN112020361A (zh) 2018-02-02 2020-12-01 阿克罗斯生物制药公司 睾酮治疗方法
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
US12544511B2 (en) 2018-06-20 2026-02-10 Koska Family Limited Systems and methods for pre-filled dual-chamber medical agent delivery
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
EP3870150A1 (en) 2018-10-26 2021-09-01 Viramal Limited Mucoadhesive gel composition
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
ES2948955T3 (es) 2018-11-30 2023-09-22 Viramal Ltd Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante
WO2020118437A1 (en) * 2018-12-14 2020-06-18 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
EP4247332B1 (en) * 2020-11-19 2026-04-22 Acousia Therapeutics GmbH Non-aqueous gel composition
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
DK1510213T3 (da) * 1997-11-10 2009-03-23 Strakan Int Ltd Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
JP2005505587A (ja) * 2001-10-12 2005-02-24 シーエヌエス・インコーポレーテッド 含水性の点鼻ゲル及びその塗布装置
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
KR101217680B1 (ko) * 2004-12-09 2013-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 산을 사용한 글루코코르티코이드 에스테르의 안정화
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
CA2664427C (en) * 2006-10-04 2012-06-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
WO2008116825A2 (en) * 2007-03-23 2008-10-02 Unimed Pharmaceuticals, Llc Compositions and method for treating pediatric hypogonadism
US8507467B2 (en) * 2007-09-20 2013-08-13 Shiseido Company, Ltd. Transdermally absorbable preparation
ES2547339T3 (es) * 2007-11-13 2015-10-05 Curadis Gmbh Esteroides C-19 para usos terapéuticos específicos
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
MX395212B (es) * 2011-05-15 2025-03-21 Acerus Biopharma Inc Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal.

Also Published As

Publication number Publication date
ZA201309265B (en) 2016-01-27
EP2714006A1 (en) 2014-04-09
KR20140033408A (ko) 2014-03-18
JP2021001206A (ja) 2021-01-07
ZA201309264B (en) 2015-09-30
JP2022078222A (ja) 2022-05-24
JP7017254B2 (ja) 2022-02-08
IL229400A0 (en) 2014-01-30
CA2836405A1 (en) 2012-11-22
AU2022202402A1 (en) 2022-05-12
KR20240162608A (ko) 2024-11-15
CA2836398C (en) 2021-12-14
CN110613679A (zh) 2019-12-27
WO2012156822A1 (en) 2012-11-22
AU2020267162A1 (en) 2020-12-03
AU2017203470A1 (en) 2017-06-22
IL229401A0 (en) 2014-01-30
EP3977982A1 (en) 2022-04-06
JP2014515038A (ja) 2014-06-26
DK2714006T3 (da) 2021-03-15
AR089553A1 (es) 2014-09-03
CN109481394A (zh) 2019-03-19
MX2019003340A (es) 2019-07-04
KR102568894B1 (ko) 2023-08-21
CN103813784A (zh) 2014-05-21
CA2836405C (en) 2021-09-07
KR20190117803A (ko) 2019-10-16
AU2019203400A1 (en) 2019-08-01
MX395212B (es) 2025-03-21
KR20200118228A (ko) 2020-10-14
JP2022105175A (ja) 2022-07-12
JP2018199701A (ja) 2018-12-20
JP6594924B2 (ja) 2019-10-23
ES2859784T3 (es) 2021-10-04
AU2020267162B2 (en) 2022-06-09
CA3034552A1 (en) 2012-11-22
CA3034552C (en) 2023-02-07
AU2019201618A1 (en) 2019-04-18
KR20210135003A (ko) 2021-11-11
JP2020079257A (ja) 2020-05-28
KR20210029849A (ko) 2021-03-16
WO2012156820A9 (en) 2014-02-20
KR20230041081A (ko) 2023-03-23
PL2714006T3 (pl) 2021-08-16
AU2012257492A1 (en) 2013-12-19
MX2020008599A (es) 2022-08-31
EP2709588B1 (en) 2021-08-25
MX363561B (es) 2019-03-27
JP2017160204A (ja) 2017-09-14
BR112013029332A2 (pt) 2021-06-01
CN109481394B (zh) 2023-05-05
BR112013029336B1 (pt) 2021-11-30
AU2019203067A1 (en) 2019-05-23
CN103796636A (zh) 2014-05-14
KR20190006194A (ko) 2019-01-17
WO2012156820A1 (en) 2012-11-22
JP2014513716A (ja) 2014-06-05
CA2836398A1 (en) 2012-11-22
EA201391701A1 (ru) 2014-04-30
MX2013013388A (es) 2014-09-15
MX2013013369A (es) 2014-10-17
EP2714006B1 (en) 2020-12-09
AU2024216312A1 (en) 2024-10-24
AU2020210227A1 (en) 2020-08-20
AU2012257490A1 (en) 2013-12-19
AU2017204182A1 (en) 2017-07-20
MX374398B (es) 2025-03-06
EP2709588A1 (en) 2014-03-26
KR20140045400A (ko) 2014-04-16
KR20200028503A (ko) 2020-03-16
BR112013029336A2 (pt) 2020-08-11
PL2714006T4 (pl) 2021-08-16
AR086409A1 (es) 2013-12-11
CN103796636B (zh) 2019-04-05
KR102088038B1 (ko) 2020-03-13
JP2020073469A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
JP6594924B2 (ja) 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
US20250064831A1 (en) Controlled release topical testosterone formulations and methods
US20250009756A1 (en) Male Testosterone Titration Methods, Male Intranasal Testosterone Bio-Adhesive Gel Formulations and Use Thereof for Treating Hypogonadism and TRT
US20240316063A1 (en) Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
HK40018181A (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
HK1196261B (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170322

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170526

R150 Certificate of patent or registration of utility model

Ref document number: 6152092

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees